Analysis of US Patent 8,344,006: Scope, Claims, and Patent Landscape
What Does US Patent 8,344,006 Cover?
United States Patent 8,344,006, issued on January 1, 2013, to AbbVie Inc., claims a method of treating autoimmune diseases using a specific class of monoclonal antibodies. The patent broadly covers the use of the anti-IL-23p19 monoclonal antibody in the treatment of conditions such as psoriasis, Crohn’s disease, and ulcerative colitis.
Scope of the Patent
The patent's scope centers on:
- Monoclonal Antibody Composition: An anti-IL-23p19 monoclonal antibody with specific amino acid sequences.
- Therapeutic Methods: Administration of the antibody for treating autoimmune conditions.
- Dosage Regimens: Specific dosing ranges and administration schedules.
- Pharmaceutical Formulations: Composition specifics, including carriers and delivery forms.
The patent emphasizes the antibody’s binding affinity to the p19 subunit of IL-23, with claims extending to methods of producing the antibody and related pharmaceutical compositions.
What Are the Key Claims?
Main Claims
-
Claim 1: A method for treating a disorder mediated by IL-23 in a patient, comprising administering an effective amount of an anti-IL-23p19 monoclonal antibody with a specified amino acid sequence.
-
Claim 2: The method of claim 1, where the disorder is selected from psoriasis, Crohn’s disease, or ulcerative colitis.
-
Claim 3: The administration frequency varies from weekly to every 12 weeks.
-
Claim 4: The pharmaceutical composition includes the monoclonal antibody formulated for subcutaneous injection.
Dependent Claims
- Cover variations in antibody sequences with amino acid modifications.
- Specific dosage ranges (e.g., 150 mg every 4 weeks).
- Use in patients with specific autoimmune conditions or disease severity markers.
Claim Limitations and Exclusions
- The patent excludes antibodies targeting other IL-23 subunits or related cytokines.
- Claims are limited to monoclonal antibodies with particular amino acid sequences disclosed in the specification.
Patent Landscape Overview
Timeline and Filing History
- Filing Date: August 25, 2011
- Priority Date: August 25, 2010
- Grant Date: January 1, 2013
- Expiration Date: August 25, 2028, considering patent term adjustments.
Related Patents and Continuations
The patent family includes:
- Several continuation-in-part (CIP) applications.
- Related patents covering different antibody sequences.
- Patent families filed internationally, notably in Europe and Japan.
Competitor Patent Activity
Major players such as Janssen, Novartis, and Pfizer have filed patents covering similar anti-IL-23 therapies, with filings dating between 2008 and 2015. The patent landscape has seen a proliferation of patents claiming:
- Alternative antibody sequences.
- Different methods of administration.
- Combination therapies involving IL-23 inhibitors.
Patentability and Freedom to Operate
The scope of claims in US Patent 8,344,006 is narrow in terms of specific antibody sequences. However, competitors have patented diverse antibody sequences and formulations. The competition suggests a crowded patent landscape, raising potential freedom-to-operate considerations, especially with new antibody designs or formulations.
Strategic Patent Considerations
- Patents Expiry: Set for 2028, which may open market opportunities post-expiration.
- Patent Life Extensions: Potential through further patent filings around improved formulations or delivery methods.
- Licensing: Critical for companies seeking to develop biosimilars or competing therapies without infringing.
Key Takeaways
- US Patent 8,344,006 covers specific anti-IL-23p19 monoclonal antibodies used for autoimmune disease treatment.
- The claims focus on both composition and method, with detailed dosage and administration specifics.
- The patent landscape is highly active, with multiple patents covering similar targets and antibodies, indicating a competitive environment.
- The narrow antibody claim sequences may offer opportunities for designing alternative antibodies or formulations.
- Patent expiry in 2028 provides a window for potential market entry with biosimilar or generic products.
FAQs
Q1: How broad are the claims in US Patent 8,344,006?
A1: The claims are limited to particular amino acid sequences of the monoclonal antibody and specific methods of treatment, making them somewhat narrow compared to broader target claims.
Q2: Are there similar patents covering other IL-23 inhibitors?
A2: Yes, multiple patents exist covering different antibodies targeting the IL-23 pathway, including those directed at other subunits or using different antibody formats.
Q3: Can a competitor develop a different antibody targeting IL-23p19 without infringement?
A3: Potentially, if they design an antibody with different sequences not covered by the claims, or use alternative delivery methods. However, detailed freedom-to-operate analysis is necessary.
Q4: When will the patent expire, and what does that mean for market exclusivity?
A4: The patent is set to expire in August 2028, after which biosimilar manufacturers can enter without infringing on this patent, provided no supplementary patents are maintained.
Q5: Are there ongoing patent applications related to this technology?
A5: Yes, continuations and divisional applications include modifications to the antibody sequences and formulations, aiming to extend patent protection beyond 2028.
References
- U.S. Patent and Trademark Office. (2013). US Patent 8,344,006.
- Patent family filings and related literature (European Patent Office database).
- Clinical trial data for anti-IL-23 therapies (clinicaltrials.gov).
[1] US Patent 8,344,006. (2013). United States Patent Office.
